Drug Profile

R 2487

Alternative Names: R-2487

Latest Information Update: 04 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Rise Therapeutics
Class Antirheumatics; Bacteria; Gene therapies; Probiotics
Mechanism of Action Bacteria replacements; Colonisation factor antigen expression stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I Rheumatoid arthritis
Clinical Phase Unknown Sjogren's syndrome

Most Recent Events

28 Jan 2026 US FDA approves IND application for R 2487 in Sjogren's syndrome (Rise Therapeutics pipeline, January 2026)
23 Sep 2025 Rise Therapeutics plans to initiated a SJD study for Sjogren's Disease (PO) 9450494
19 Oct 2023 Phase-I clinical trials in Rheumatoid arthritis (Treatment-experienced) in USA (PO) (NCT05961592)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com